LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Inicio・Lista de Acciones・Denali Therapeutics Inc

Denali Therapeutics Inc

Cerrado

SectorSalud

19.6 -0.41

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

19.1

Máximo

19.83

Métricas clave
By Trading Economics
Ingresos	-2.8M -127M
Empleados	517
EBITDA	-2M -123M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+59.98% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	418M 2.7B
Apertura anterior	20.01
Cierre anterior	19.6

Noticias sobre sentimiento de mercado

By Acuity

25%

75%

63 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

13.355 / 16.44 Soporte y Resistencia

Denali Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 dic 2025, 22:13 UTC

Ganancias

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 dic 2025, 21:40 UTC

Ganancias

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 dic 2025, 18:51 UTC

Adquisiciones, fusiones, absorciones

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 dic 2025, 16:57 UTC

Principales Movimientos del Mercado

Clear Secure Rises on Medicare Identity Verification Contract

9 dic 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 dic 2025, 23:46 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings Stake in Lenovo Now at 32.34%

9 dic 2025, 23:45 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 dic 2025, 23:44 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 dic 2025, 23:43 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 dic 2025, 23:43 UTC

Adquisiciones, fusiones, absorciones

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 dic 2025, 23:35 UTC

Charlas de Mercado

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 dic 2025, 22:42 UTC

Ganancias

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 dic 2025, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

9 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 dic 2025, 21:48 UTC

Charlas de Mercado

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Ganancias

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 dic 2025, 20:28 UTC

Charlas de Mercado

Oil Futures Decline for Second Straight Session -- Market Talk

9 dic 2025, 20:27 UTC

Adquisiciones, fusiones, absorciones

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 dic 2025, 20:27 UTC

Adquisiciones, fusiones, absorciones

Teck Reports Voting Results From Special Meeting of Hldrs

9 dic 2025, 20:26 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 dic 2025, 20:21 UTC

Charlas de Mercado

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 dic 2025, 19:52 UTC

Ganancias

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 dic 2025, 19:17 UTC

Ganancias

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 dic 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

9 dic 2025, 17:11 UTC

Ganancias

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Comparación entre iguales

Cambio de precio

Denali Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

59.98% repunte

Estimación a 12 meses

Media 31.5 USD 59.98%

Máximo 37 USD

Mínimo 26 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Denali Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Denali Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

13.355 / 16.44Soporte y Resistencia

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentimiento

By Acuity

63 / 374 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.